Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 14/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602190 | 0.94 | AR (0.56) | AR | |
| SCHEMBL3598414 | 0.89 | AR (0.57) | AR | |
| SCHEMBL7519811 | 0.85 | CHRM4 (0.45) | — | |
| SCHEMBL3613663 | 0.84 | AR (0.51) | AR | |
| SCHEMBL3605550 | 0.84 | AR (0.64) | AR | |
| SCHEMBL4881177 | 0.82 | AR (0.69) | AR | |
| SCHEMBL3611354 | 0.82 | AR (0.61) | AR | |
| SCHEMBL3607872 | 0.81 | AR (0.59) | AR | |
| SCHEMBL3605320 | 0.80 | AR (0.58) | AR | |
| SCHEMBL3592380 | 0.79 | AR (0.69) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152111-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | ASTRAZENECA UK LIMITED (GB) | 2015-06-04 | — | — | US | disclosed |
| US-20140296258-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITON | ASTRAZENECA UK LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| EP-1553074-B1 | FUSED BENZENE DERIVATIVE AND USE | TAKEDA PHARMACEUTICAL (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-20130109702-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | ASTRAZENECA AB (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130072503-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | ASTRAZENECA (GB) | 2013-03-21 | — | — | US | disclosed |
| US-20120165348-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| US-20100069408-A1 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition | ASTRAZENECA AB (SE) | 2010-03-18 | — | — | US | disclosed |
| US-7649001-B2 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-19 | — | — | US | disclosed |
| US-20090042857-A1 | Novel Pharmaceutical | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-1987827-A1 | NOVEL PHARMACEUTICAL | Takeda Pharmaceutical Company Limited (JP) | 2008-11-05 | — | — | EP | disclosed |
| US-20080214812-A1 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-7250419-B2 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition | ASTRAZENECA AB (SE) | 2007-07-31 | — | — | US | disclosed |
| US-20060106067-A1 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1553074-A1 | FUSED BENZENE DERIVATIVE AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-0996621-B1 | TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS ANTI-THROMBOTIC AGENTS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| EP-1056749-B1 | NOVEL TRIAZOLO(4,5-d)PYRIMIDINE COMPOUNDS | ASTRAZENECA UK LTD (GB) | 2003-02-19 | — | — | EP | disclosed |
| US-6369064-B1 | MYOCARDIAL INFARCTION AND UNSTABLE ANGINA; P2T-RECEPTOR ANTAGONISTS; ANTITHROMBOTIC AGENTS; 7-(SUBSTITUTED AMINO) -5-(THIO)-3H-1,2,3-TRIAZOLO(4,5-D)PYRIMIDIN-3-YL) -CYCLOPENTANECARBOXAMIDES | ASTRAZENECA AB (SE) | 2002-04-09 | — | — | US | disclosed |
| US-6251910-B1 | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists | ASTRAZENECA UK LIMITED (GB) | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165348-A1 | Novel compounds | P2RX5, P2RX4, P2RY4 | AR 4491/4885 |
| US-20060106067-A1 | Fused benzene derivative and use | AR, NR5A1, CBR3 | AR 1/4885 |
| US-20150152111-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | THPO, PF4, P2RY4 | AR 4788/4885 |
| US-20080214812-A1 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition | THPO, PF4, P2RY4 | AR 4788/4885 |
| US-20100069408-A1 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition | THPO, PF4, P2RY4 | AR 4788/4885 |
| US-20140296258-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITON | GP6, THPO, P2RY6 | AR 4745/4885 |
| US-20090042857-A1 | Novel Pharmaceutical | AR, NR5A1, NR5A2 | AR 1/4885 |
| US-20130072503-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | THPO, PF4, P2RY4 | AR 4788/4885 |
| US-20130109702-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | THPO, PF4, P2RY4 | AR 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.